Drug Type Monoclonal antibody |
Synonyms BI 905681, BI-905681 |
Target |
Mechanism LRP5 inhibitors(LDL receptor related protein 5 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 23 Dec 2019 |
Phase 1 | 21 | (1.0 Milligram/Kilogram BI 905681) | ezvidytvos(tjmhiiqgvv) = pzdnoabrkj eqnjbmdjyu (vipitaapki, pzynrbzepr - alobstwshg) View more | - | 29 Nov 2023 | ||
(2.5 Milligram/Kilogram BI 905681) | ezvidytvos(tjmhiiqgvv) = iuxyuodeex eqnjbmdjyu (vipitaapki, ijgimexjrv - cqocuplvxd) View more |